trending Market Intelligence /marketintelligence/en/news-insights/trending/fxB63QvJdqMzurpd2QWlRQ2 content esgSubNav
In This List

Aileron Therapeutics files for $69M IPO

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Aileron Therapeutics files for $69M IPO

Aileron Therapeutics Inc. filed for an IPO of up to $69.0 million of its common stock.

The company plans to apply for listing of common stock on the Nasdaq Global Market under the symbol ALRN.

Aileron plans to use the net proceeds from the offering to fund ongoing clinical trials of ALRN-6924, to fund additional research and clinical development activity related to ALRN-6924 and other programs, and for working capital and other general corporate purposes.

Merrill Lynch Pierce Fenner & Smith Inc., Jefferies LLC, William Blair & Co. LLC and Canaccord Genuity Inc. are acting as underwriters in the offering.

Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of therapeutics called stapled peptides.